BioCentury
ARTICLE | Company News

Access Pharmaceuticals, Dong-A Pharmaceutical deal

February 23, 2009 8:00 AM UTC

Dong-A received an exclusive license to manufacture, develop and commercialize Access' MuGard for oral mucositis and ProLindac for an undetermined cancer indication in Korea. Dong-A is responsible f...